v3.25.3
Nature of Organization and Operations - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 43 Months Ended
Apr. 16, 2025
Mar. 25, 2025
Dec. 20, 2024
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Dec. 31, 2024
Dec. 19, 2024
Mar. 17, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]                              
Accumulated deficit       $ 329,999           $ 329,999   $ 329,999 $ 332,654    
Net Income (Loss)       (17,746) $ (52,615) $ 73,016 $ (12,546) $ (14,583) $ (18,289) 2,655 $ (45,418)        
Cash, cash equivalents, and short-term investments       162,600           162,600   $ 162,600      
Payment for in-licensing       $ 14,345     $ 9,997     71,942 $ 36,683        
Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations | Aadi Subsidiary                              
Organization Consolidation And Presentation Of Financial Statements [Line Items]                              
Disposal group, including discontinued operation, ownership percentage in disposed business                           100.00%  
Proceeds from divestiture of businesses   $ 102,400               $ 102,400          
Sales Agreement                              
Organization Consolidation And Presentation Of Financial Statements [Line Items]                              
Issuance of common stock (in shares)                       0      
Common Stock                              
Organization Consolidation And Presentation Of Financial Statements [Line Items]                              
Issuance of common stock (in shares)           21,592,000                  
WuXi Biologics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                              
Organization Consolidation And Presentation Of Financial Statements [Line Items]                              
Payment for in-licensing $ 38,000   $ 6,000                        
Value fee percentage 6.00%                            
Cowen and Company LLC | Common Stock | Sales Agreement                              
Organization Consolidation And Presentation Of Financial Statements [Line Items]                              
Maximum aggregate offering prices                             $ 75,000